Cognition Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. Its lead candidate, zervimesine (also known as CT1812), is an investigational oral small molecule designed to penetrate the blood-brain and blood-retina barriers, selectively bind to the sigma-2 receptor complex, and restore normal neuronal functions such as autophagy, cholesterol biosynthesis, vesicle trafficking, and protein stabilization. The company is advancing zervimesine through clinical programs in Alzheimer’s disease, including mild-to-moderate and early stages, as well as dementia with Lewy bodies and geographic atrophy secondary to dry age-related macular degeneration. These efforts encompass Phase 2 and planned Phase 3 studies evaluating safety, tolerability, cognition, function, and neuropsychiatric outcomes, alongside expanded access programs. Founded in 2007 and headquartered in Purchase, New York, Cognition Therapeutics Inc. plays a role in addressing unmet needs in neurodegenerative and neuro-ophthalmic diseases by modulating cellular damage response mechanisms.